Formalin fixation on HER-2 and PD-L1 expression in gastric cancer:A pilot analysis using the same surgical specimens with different fixation times

被引:1
|
作者
Keita Kai
Yukie Yoda
Atsushi Kawaguchi
Akimichi Minesaki
Hironori Iwasaki
Shinichi Aishima
Hirokazu Noshiro
机构
[1] Department of Pathology, Saga University Hospital
[2] Department of Surgery, Saga University Faculty of Medicine
[3] Center for Comprehensive Community Medicine, Saga University Faculty of Medicine
[4] Department of Pathology and Microbiology, Saga University Faculty of Medicine
[5] Department of Otolaryngology - Head and Neck Surgery, Saga University Faculty of Medicine
关键词
Gastric cancer; Programmed death-ligand 1; Human epidermal growth factor receptor 2; Neutral buffered formalin; Fixation time;
D O I
暂无
中图分类号
R735.2 [胃肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND The needs for human epidermal growth factor receptor 2(HER-2) and/or programmed death-ligand 1(PD-L1) evaluations in gastric cancer are dramatically increasing. Although the importance of standardization of sample fixation has been widely recognized, most of the evidence regarding the fixation duration or type of fixing solution are based on breast cancer.AIM To investigate the real effects of fixation conditions on HER-2 testing or PD-L1 testing for gastric cancer using gastrectomy specimens.METHODS Thirty-two patients who underwent gastrectomy for gastric cancer were enrolled.Their resected specimens were each divided into four pieces and fixed in four strictly controlled different durations(6 h, 24 h, and 48 h, and 1 wk) by 10%formalin(n = 22) or 10% neutral buffered formalin(NBF)(n = 10).Immunohistochemistry(IHC) of HER-2 and PD-1 was performed, and a pathology examination was conducted. In the HER-2-immunoreactive cases, all four specimens were subjected to dual-color in situ hybridization(DISH). Five cases were assessed as HER-2-positive by IHC and DISH. We used the cut-off values of 1%, 10%, and 50% to assess the IHC findings of PD-L1.RESULTS No significant difference was observed in comparisons between the shorter fixation period groups(6 h, 24 h, and 48 h) and the prolonged fixation period(1 wk) group in the HER-2 and PD-L1 analyses. Although no significant difference was observed between 10% formalin and 10% NBF within 1 wk of fixation, the superiority of 10% NBF was confirmed in a long-term(> 3 mo) fixation in both the HER-2 and PD-L1 analyses.CONCLUSION In this small-numbered pilot study, prolonged fixation within 1 wk showed no inferiority in HER-2 or PD-L1 testing. However, a large-numbered prospective study is needed to obtain conclusive results.
引用
收藏
页码:419 / 430
页数:12
相关论文
共 50 条
  • [21] AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer
    Spirina, L. V.
    Avgustinovich, A. V.
    Afanas'ev, S. G.
    Kondakova, I. V.
    Volkov, M. Yu.
    Dobrodeev, A. Yu.
    Boronkina, A. I.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2020, 170 (01) : 75 - 78
  • [22] Different expression of programmed death 1 (PD1) and its ligand (PD-L1) in esophageal and gastric cancer
    Daster, Silvio
    Eppenberger-Castori, Serenella
    Droeser, Raoul A.
    Schaefer, Hannah M.
    Spagnoli, Giulio C.
    Terracciano, Luigi
    Tornillo, Luigi
    von Holzen, Urs
    CANCER RESEARCH, 2016, 76
  • [23] PD-L1 Expression in Biopsies and Surgical Specimens of Lung Cancer: Impact of Biopsy Methods and Neoadjuvant Therapy
    Hoda, M. A.
    Sinn, K.
    Brugger, J.
    Bernitzky, D.
    Mosleh, B.
    Prosch, H.
    Geleff, S.
    Hoetzenecker, K.
    Idzko, M.
    Gompelmann, D.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S202 - S203
  • [24] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Sasagu Kurozumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Takaaki Fujii
    Jun Horiguchi
    Tetsunari Oyama
    Masafumi Kurosumi
    Ken Shirabe
    Scientific Reports, 9
  • [25] Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
    Kurozumi, Sasagu
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Fujii, Takaaki
    Horiguchi, Jun
    Oyama, Tetsunari
    Kurosumi, Masafumi
    Shirabe, Ken
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [26] Prevalence of CLDN18.2, HER2 and PD-L1 in gastric cancer samples
    Moran, D.
    Maurus, D.
    Rohde, C.
    Arozullah, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Comparison of PD-L1 Expression Between Preoperative Biopsy Specimens and Surgical Specimens in Non-Small Cell Lung Cancer
    Sakaguchi, Tadashi
    Iketani, Akemi
    Ito, Kentaro
    Nishii, Yoichi
    Katsuta, Koji
    Hataji, Osamu
    CANCERS, 2025, 17 (03)
  • [28] COMPARISON OF PD-L1 EXPRESSION BETWEEN PREOPERATIVE BIOPSY SPECIMENS AND SURGICAL SPECIMENS IN NON-SMALL CELL LUNG CANCER
    Sakaguchi, Tadashi
    Itou, Kentarou
    Hataji, Osamu
    CHEST, 2024, 166 (04) : 4392A - 4392A
  • [29] Helicobacter pylori infection and PD-L1 expression in gastric cancer: A meta-analysis
    Zhu, Yaodong
    Zhu, Fangyuan
    Ba, He
    Chen, Jie
    Bian, Xiuliang
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (02)
  • [30] TRPV2 regulates PD-L1 expression and binding ability to PD-1 in gastric cancer
    Shiozaki, Atsushi
    Fukami, Tomoyuki
    Shimizu, Hiroki
    Kosuga, Toshiyuki
    Kudou, Michihiro
    Nishibeppu, Keiji
    Ohashi, Takuma
    Arita, Tomohiro
    Konishi, Hirotaka
    Komatsu, Shuhei
    Kubota, Takeshi
    Fujiwara, Hitoshi
    Otsuji, Eigo
    CANCER SCIENCE, 2024, 115 : 587 - 587